Angiostatins

Subscribe to Selected New Research on Angiostatins

344 relevant articles (34 outcomes, 52 trials/studies) found for this Bio-Agent

Description: Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity.

Also Known As:

Angiostatin

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Enzyme Precursors: 134

Plasminogen: 1773

Angiostatins: 344

human angiostatin4.5

Biological Factors: 931

Intercellular Signaling Peptides and Proteins: 9177

Angiogenic Proteins: 77

Angiostatic Proteins: 6

Angiostatins: 344

human angiostatin4.5

Experts

1.	Opolon, Paule: 4 articles (11/2003 - 06/2003)
2.	Weihrauch, Dorothee: 3 articles (09/2007 - 05/2004)
3.	Chilian, William M: 3 articles (05/2005 - 05/2004)
4.	Griscelli, Frank: 3 articles (11/2003 - 06/2003)
5.	Voest, E E: 3 articles (01/2003 - 03/2000)
6.	Indraccolo, S: 3 articles (07/2002 - 07/2001)
7.	Cao, Y: 3 articles (07/2001 - 05/2000)
8.	Bigam, David L: 2 articles (10/2007 - 01/2007)
9.	Kim, Byung-Tae: 2 articles (10/2007 - 07/2003)
10.	Paik, Jin-Young: 2 articles (10/2007 - 07/2003)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2002 - "The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors." 01/01/2004 - "These studies demonstrate the feasibility of using AAV anti-angiogenic gene therapy as a cancer treatment modality and suggest that the optimal anti-tumor efficacy of angiostatin following gene transfer may be limited to a narrow dose range." 01/01/2004 - "The aim is to shed light on areas in which more research is needed with respect to angiostatin and other anti-angiogenic agents and the microenvironmental conditions that affect their activities, in order to develop improved therapeutic strategies for diabetic cancer patients." 11/01/2000 - "These data suggest that low pH(e) plays a role in the relative specificity and efficacy of angiostatin for tumor neovasculature and indicate roles for both pH(e) and pH(i) in the mechanism of angiostatin action. " 11/01/2002 - "Our current study evaluated whether anti-tumor immune response could also potentiate the therapuetic efficacy of another antiangiogenic drug, angiostatin. " Order ALL the reference details at left...
2.	Corneal Neovascularization 05/15/2007 - "MAb3D5AB1 disrupts tube formation and decreases intracellular pH in endothelial cells exposed to low extracellular pH. Neither angiostatin nor MAb3D5AB1 showed an antiangiogenic effect in the corneal neovascularization assay; however, both were effective in the low-pH environment of the chicken chorioallantoic membrane assay. " 01/01/2007 - "The area of corneal neovascularization was significantly lower in eyes injected with rAAV-angiostatin (p<0.01) than in eyes injected with the control virus. " 01/01/2005 - "Because corneal cells generate angiostatins, use of human angiostatins may be a means of treating abnormal corneal neovascularization without the risk of side effects." 08/01/2002 - "CLINICAL RELEVANCE: This appears to be the first evidence of biologically induced regression of corneal neovascularization, and the first direct demonstration of angiostatin-induced regression of neovascularization in any tissue." 08/01/2002 - "In a second experiment, recombinant angiostatin was delivered continuously for 2 weeks via an osmotic pump in mice with established corneal neovascularization. " Order ALL the reference details at left...
3.	Neoplasm Metastasis (Metastasis) 01/01/2008 - "Our results suggest that the biological activity of angiostatin as a putative metastasis inhibitor may be in part the result of nm23 inhibition and that the production, lyophilization, packaging or storage of commercial angiostatin leads to the alteration of its biological activity against NDPK-B. " 11/14/2003 - "Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity." 01/01/2003 - "Angiostatin prolongs the survival of mice with leptomeningeal metastases." 03/19/2001 - "Angiostatin, a circulating inhibitor of angiogenesis, was identified by its ability to maintain dormancy of established metastases in vivo. " 01/01/2000 - "CONCLUSION: Angiostatin markedly inhibits the growth and metastasis of LA795 cells on T739 mice and no obvious side effects of angiostatin were found during the treatment." Order ALL the reference details at left...
4.	Pancreatic Neoplasms (Pancreatic Cancer) 08/01/2002 - "Experimental study of gene therapy with angiostatin gene in pancreatic cancer." 08/28/2005 - "CONCLUSION: Angiostatin does not directly inhibit human pancreatic cancer cell proliferation and growth in vitro, but it inhibits endothelial cell growth in vitro. " 08/28/2005 - "AIM: To observe the biologic behavior of pancreatic cancer cells in vitro and in vivo, and to explore the potential value of angiostatin gene therapy for pancreatic cancer. " 08/28/2005 - "Angiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice." 08/01/1998 - "We have previously shown that the human pancreatic cancer cell line ASPC-1 produces enzymatic activity capable of generating angiostatin. " Order ALL the reference details at left...
5.	Experimental Arthritis 01/01/2003 - "For instance, intraarticular application of the angiostatic molecule angiostatin reduces the severity of collagen-induced arthritis in mice. " 03/01/2002 - "OBJECTIVE: To determine the efficacy of local therapy with human angiostatin gene in murine collagen-induced arthritis (CIA). " 09/01/2005 - "These results indicate that the HIV vector-mediated expression of angiostatin efficiently inhibits the progression of collagen-induced arthritis. " 09/01/2005 - "Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice." 07/01/2005 - "CONCLUSION: AAV-vector-mediated local expression of angiostatin efficiently inhibited the development of collagen-induced arthritis in the treated joint. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Endostatins
2.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
3.	Angiogenesis Inhibitors
4.	Retinaldehyde (Retinal)
5.	Tissue Inhibitor of Metalloproteinase-2
6.	Dendrimers (Dendrons)
7.	glucuronyl glucosamine glycan sulfate (Vessel)
8.	pigment epithelium-derived factor
9.	Angiogenesis Inducing Agents (Angiogenesis Factor)
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Subcutaneous Injections
4.	Immunotherapy
5.	Hepatectomy

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>